The New England journal of medicine, 2020-10, Vol.383 (14), p.1328-1339
- Herbst, Roy S
- Giaccone, Giuseppe
- de Marinis, Filippo
- Reinmuth, Niels
- Vergnenegre, Alain
- Barrios, Carlos H
- Morise, Masahiro
- Felip, Enriqueta
- Andric, Zoran
- Geater, Sarayut
- Özgüroğlu, Mustafa
- Zou, Wei
- Sandler, Alan
- Enquist, Ida
- Komatsubara, Kimberly
- Deng, Yu
- Kuriki, Hiroshi
- Wen, Xiaohui
- McCleland, Mark
- Mocci, Simonetta
- Jassem, Jacek
- Spigel, David R
2020
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Herbst, Roy S
- Giaccone, Giuseppe
- de Marinis, Filippo
- Reinmuth, Niels
- Vergnenegre, Alain
- Barrios, Carlos H
- Morise, Masahiro
- Felip, Enriqueta
- Andric, Zoran
- Geater, Sarayut
- Özgüroğlu, Mustafa
- Zou, Wei
- Sandler, Alan
- Enquist, Ida
- Komatsubara, Kimberly
- Deng, Yu
- Kuriki, Hiroshi
- Wen, Xiaohui
- McCleland, Mark
- Mocci, Simonetta
- Jassem, Jacek
- Spigel, David R
- Titel
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
- Ist Teil von
- The New England journal of medicine, 2020-10, Vol.383 (14), p.1328-1339
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Among patients with lung cancer that expressed programmed death ligand 1, the anti–PD-L1 antibody atezolizumab was compared with chemotherapy in a randomized trial. In the subgroup with the highest PD-L1 expression, the median overall survival was 20.2 months with atezolizumab and 13.1 months with chemotherapy.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1917346Titel-ID: cdi_proquest_journals_2447572660
- Format
- –
- Schlagworte
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized - adverse effects, Antibodies, Monoclonal, Humanized - therapeutic use, Antineoplastic Agents - adverse effects, Antineoplastic Agents - therapeutic use, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Apoptosis, B7-H1 Antigen - metabolism, Carboplatin - administration & dosage, Carcinoma, Non-Small-Cell Lung - drug therapy, Carcinoma, Non-Small-Cell Lung - genetics, Carcinoma, Non-Small-Cell Lung - metabolism, Carcinoma, Non-Small-Cell Lung - mortality, Carcinoma, Squamous Cell - drug therapy, Chemotherapy, Cisplatin - administration & dosage, Deoxycytidine - administration & dosage, Deoxycytidine - analogs & derivatives, Epidermal growth factor receptors, Female, Humans, Immunotherapy, Lung cancer, Lung Neoplasms - drug therapy, Lung Neoplasms - genetics, Lung Neoplasms - metabolism, Lung Neoplasms - mortality, Male, Metastases, Metastasis, Middle Aged, Monoclonal antibodies, Mutation, Non-small cell lung carcinoma, PD-L1 protein, Platinum, Population, Small cell lung carcinoma, Survival Analysis, Targeted cancer therapy, Translocation, Tumor cells, Tumor-infiltrating lymphocytes, Tumors